Jane Street’s C4 Therapeutics CCCC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.41M Sell
302,750
-944,146
-76% -$3.23M ﹤0.01% 5799
2026
Q1
$3.28M Buy
1,246,896
+372,102
+43% +$876K ﹤0.01% 4182
2025
Q4
$1.67M Buy
874,794
+671,226
+330% +$1.59M ﹤0.01% 5162
2025
Q3
$452K Sell
203,568
-289,044
-59% -$694K ﹤0.01% 8076
2025
Q2
$704K Buy
492,612
+480,035
+3,817% +$698K ﹤0.01% 6288
2025
Q1
$20.1K Sell
12,577
-140,197
-92% -$418K ﹤0.01% 9152
2024
Q4
$550K Buy
152,774
+83,323
+120% +$414K ﹤0.01% 6587
2024
Q3
$396K Sell
69,451
-62,415
-47% -$376K ﹤0.01% 7584
2024
Q2
$609K Buy
131,866
+77,752
+144% +$464K ﹤0.01% 6697
2024
Q1
$442K Sell
54,114
-144,557
-73% -$1.12M ﹤0.01% 6892
2023
Q4
$1.12M Buy
+198,671
New +$453K ﹤0.01% 5349
2023
Q3
Sell
-98,565
Closed -$271K 8685
2023
Q2
$271K Sell
98,565
-2,176
-2% -$6.99K ﹤0.01% 7277
2023
Q1
$316K Buy
+100,741
New +$593K ﹤0.01% 7102
2022
Q2
Sell
-20,231
Closed -$178K 9724
2022
Q1
$491K Buy
+20,231
New +$491K ﹤0.01% 7528
2021
Q2
Sell
-5,699
Closed -$211K 9808
2021
Q1
$211K Buy
+5,699
New +$227K ﹤0.01% 8195

Other funds holding CCCC

Jane Street's CCCC Position: Q2 2026 in Review

Jane Street reduced its C4 Therapeutics (CCCC) stake by 76% in Q2 2026, selling an estimated $3.23M and leaving 302,750 shares worth $1.41M. The position accounts for ﹤0.01% of the portfolio, ranked #5799.

Jane Street first reported a position in CCCC in Q1 2021 and has held it in 15 quarters since. The position peaked at $3.28M in Q1 2026. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Jane Street held 302,750 shares of C4 Therapeutics worth $1.41M as of Q2 2026.
  • Jane Street sold 944,146 C4 Therapeutics shares in Q2 2026, an estimated $3.23M.
  • C4 Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #5799 holding.
  • Jane Street first reported a position in C4 Therapeutics in Q1 2021 and has held it in 15 quarters since.
  • Jane Street's C4 Therapeutics position peaked at $3.28M in Q1 2026.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.